Venetoclax

Generic Name
Venetoclax
Brand Names
Venclexta, Venclyxto
Drug Type
Small Molecule
Chemical Formula
C45H50ClN7O7S
CAS Number
1257044-40-8
Unique Ingredient Identifier
N54AIC43PW
Background

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .

Indication

本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。

Associated Conditions
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Associated Therapies
-
Clinical Trials
Related News

Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

First Posted Date
2021-08-13
Last Posted Date
2023-08-01
Lead Sponsor
Melbourne Health
Target Recruit Count
18
Registration Number
NCT05005299
Locations
🇦🇺

Melbourne Health, Melbourne, Victoria, Australia

Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma

First Posted Date
2021-08-04
Last Posted Date
2022-03-10
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT04990778
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

First Posted Date
2021-07-26
Last Posted Date
2024-08-02
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
20
Registration Number
NCT04975919
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

First Posted Date
2021-07-16
Last Posted Date
2024-11-19
Lead Sponsor
Loxo Oncology, Inc.
Target Recruit Count
600
Registration Number
NCT04965493
Locations
🇺🇸

The James Cancer Hospital, Columbus, Ohio, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Houston Methodist Hospital, Houston, Texas, United States

and more 214 locations

Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

Phase 1
Active, not recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Azacitidine
Drug: Uproleselan
Drug: Venetoclax
First Posted Date
2021-07-16
Last Posted Date
2024-08-01
Lead Sponsor
Brian Jonas
Target Recruit Count
16
Registration Number
NCT04964505
Locations
🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

First Posted Date
2021-06-28
Last Posted Date
2024-11-19
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
20
Registration Number
NCT04941716
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

First Posted Date
2021-06-25
Last Posted Date
2024-06-04
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
8
Registration Number
NCT04939272
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients with Hematological Malignancies

First Posted Date
2021-06-23
Last Posted Date
2024-10-15
Lead Sponsor
Kahr Medical
Target Recruit Count
36
Registration Number
NCT04937166
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, Texas, United States

Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)

First Posted Date
2021-06-15
Last Posted Date
2024-05-31
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
30
Registration Number
NCT04926285
Locations
🇺🇸

University of Illinois Cancer Center, Chicago, Illinois, United States

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

First Posted Date
2021-06-03
Last Posted Date
2024-02-26
Lead Sponsor
AbbVie
Target Recruit Count
40
Registration Number
NCT04912063
Locations
🇮🇱

Hadassah Medical Center-Hebrew University /ID# 227275, Jerusalem, Yerushalayim, Israel

🇦🇺

Austin Health /ID# 227717, Heidelberg, Victoria, Australia

🇮🇱

Rabin Medical Center /ID# 227738, Petakh Tikva, Israel

and more 26 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy